Gudjonsdottir Bjorg, Hjaltason Haukur, Andresdottir Gudbjorg Thora
Department of Physical Therapy, School of Health Sciences, University of Iceland.
Faculty of Medicine, School of Health Sciences, University of Iceland, Department of Neurology, National University Hospital, Iceland.
Laeknabladid. 2021 Apr;107(4):179-184. doi: 10.17992/lbl.2021.04.630.
Fampridine is a drug for people with Multiple Sclerosis (MS). It is a broad-spectrum voltage-dependent potassium channel blocker that enhances synaptic transmission. The drug has been shown to be able to enhance conduction in demyelinated axons, thereby leading to improved gait in patients with MS. The purpose of this study was to examine the effect of fampridine on gait function in people with MS in the end of a 2 weeks trial drug period and to observe how many patients continued drug therapy.
Data from 41 individuals with MS was collected retrospectively for this study. Measurements were administered by physiotherapists and the results from the Timed 25-Foot Walk (T25FW) and 12-item Multiple Sclerosis Walking Scale (MSWS-12) were obtained from medical records from The National University Hospital of Iceland.
The results showed a significant difference in walking speed before and at the end of trial period (p<0.0001). The average improvement in walking speed was 22%. Results also demonstrated a significant difference in MSWS-12 scores before and at the end of treatment (p<0.0001). The average improvement in MSWS-12 was 11.4 points. Eighteen individuals (43.9%) continued treatment after the trial period.
Fampridine can have a positive effect on impaired gait function in people with MS and can be an important adjunct to treatment.
氨吡啶是一种用于治疗多发性硬化症（MS）患者的药物。它是一种广谱电压依赖性钾通道阻滞剂，可增强突触传递。已证明该药物能够增强脱髓鞘轴突的传导，从而改善MS患者的步态。本研究的目的是在为期2周的药物试验期结束时，研究氨吡啶对MS患者步态功能的影响，并观察有多少患者继续接受药物治疗。
本研究回顾性收集了41例MS患者的数据。测量由物理治疗师进行，25英尺定时步行（T25FW）和12项多发性硬化症步行量表（MSWS-12）的结果来自冰岛国立大学医院的医疗记录。
结果显示试验期开始和结束时的步行速度存在显著差异（p<0.0001）。步行速度的平均改善率为22%。结果还表明治疗开始和结束时MSWS-12评分存在显著差异（p<0.0001）。MSWS-12的平均改善为11.4分。18名患者（43.9%）在试验期后继续接受治疗。
氨吡啶可对MS患者受损的步态功能产生积极影响，并且可以成为治疗的重要辅助手段。
